Actemra May Treat Severe COVID-19 Infections in Myeloma Patients, Case Report Suggests
Actemra (tocilizumab), a medicine approved for certain types of arthritis, may be effective in treating severe infections with the new coronavirus in…
Myeloma
Industry leaders seek to advance innovative resources for rare and orphan disease communities amid COVID-19 outbreak
FFF Enterprises and Bionews announced today that both rare and orphan disease advocates are joining forces to provide patients with resources to help them connect…
Surge in Telemedicine One ‘Good’ Outcome from COVID-19 Crisis, Doctors Say
While there are few silver linings to the cloud created by COVID-19, the pandemic that has killed tens of thousands, hobbled economies worldwide and drove…
Spain Reviewing Trial to Treat COVID-19 Pneumonia With Myeloma Therapy Aplidin
Madrid-based PharmaMar has submitted the protocol for a Phase 2 trial to the Spanish Medicines and Healthcare Products Agency (AEMPS) to test its multiple…
Bristol Myers, Bluebird Bio Seek FDA Approval of Ide-cel to Treat Advanced Multiple Myeloma
Bristol Myers Squibb and Bluebird Bio are seeking U.S. approval of their lead investigational CAR T-cell therapy —…
Melflufen Shows Positive Response in Triple-refractory Multiple Myeloma Trial
Topline results show a 26% response rate in a Phase 2 clinical trial evaluating melflufen (melphalan flufenamide)…
Oncopeptides’ Accelerated Approval Filing for Melflufen in US Unimpeded by COVID-19
Despite some interruptions to melflufen‘s (melphalan flufenamide) clinical program due to the ongoing COVID-19 outbreak, Oncopeptides‘ application seeking its accelerated approval in…
Genetic Test May Help Identify Ultra High-risk Multiple Myeloma
A novel genetic test could help identify people with multiple myeloma who are at highest risk of aggressive disease and unlikely to respond to standard…
Ninlaro Combo Fails to Extend New Myeloma Patients’ Survival Without Disease Worsening
A combination of Ninlaro (ixazomib), Revlimid (lenalidomide), and dexamethasone failed to significantly extend the time to disease progression or death in people…
FDA Names Arcellx’s Cell Therapy CART-ddBCMA Orphan Drug for Multiple Myeloma
Arcellx’s CART-ddBCMA — a CAR T-cell therapy targeting the BCMA protein — was granted orphan drug status by the U.S.
